

U.S.S.N.: 08/823,999  
Filed: March 25, 1997  
AMENDMENT

**Appendix: Claims as pending upon entry of this amendment**

1. (amended) A method of inhibiting or reducing stenosis or restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof, comprising:

administering systemically or at the site of the injury a pharmaceutically acceptable composition comprising a compound which specifically inhibits or reduces leukocyte CD11/CD18 integrin-mediated adhesion or function, wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with CD11/CD18 integrins or their ligands and which block the interaction of the CD11/CD18 integrins or their ligands with vascular cells; molecules which inhibit expression of the CD11/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the CD11/CD18 integrins or their ligands which block the interaction of the CD11/CD18 integrins or their ligands with vascular cells or tissues, in an amount effective to inhibit or reduce stenosis or dependent restenosis of a blood vessel following injury to vascular tissue.

2. The method of claim 1 wherein the leukocytes are monocytes or granulocytes.

3. The method of claim 1 wherein the injury arises from angioplasty, atherectomy, endovascular stenting, coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs.

4. The method of claim 1 wherein the composition is in a form selected from the group consisting of solutions, gels, foams, suspensions, polymeric carriers, and liposomes.

5. (amended) The method of claim 1 wherein the integrin is selected from the group consisting of Mac-1 (CD11b/CD18), LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18.

6. (amended) The method of claim 5 wherein the CD11/CD18 integrin is Mac-1.

7. The method of claim 6 wherein the ligand is selected from the group consisting of ICAM-1, fibrin(ogen), C3bi, and factor X.

8. (amended) The method of claim 1 wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with CD11/CD18 integrins or their ligands and which block the interaction of the CD11/CD18 integrins or their ligands with vascular cells; molecules which inhibit expression of the integrins or their ligands, and peptides and peptidomimetics derived from the integrins or their ligands which block the interaction of the integrins or their ligands with vascular cells or tissues].

9. (amended) The method of claim 5 wherein the CD11/CD18 integrin is LFA-1 and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.

10. The method of claim 6 wherein the compound is an antibody or antibody fragment immunoreactive with Mac-1.

11. The method of claim 1 wherein the compound is administered to a patient in need thereof prior to vascular intervention.

12. The method of claim 11 wherein the compound is administered to a the patient prior to and after vascular intervention, until healing has occurred.